170 related articles for article (PubMed ID: 11509473)
1. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP.
Siragy HM; de Gasparo M; El-Kersh M; Carey RM
Hypertension; 2001 Aug; 38(2):183-6. PubMed ID: 11509473
[TBL] [Abstract][Full Text] [Related]
2. Differences in AT2 -receptor stimulation between AT1 -receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP.
Siragy HM; El-Kersh MA; De Gasparo M; Webb RL; Carey RM
J Hypertens; 2002 Jun; 20(6):1157-63. PubMed ID: 12023686
[TBL] [Abstract][Full Text] [Related]
3. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats.
Siragy HM; Carey RM
J Clin Invest; 1997 Jul; 100(2):264-9. PubMed ID: 9218502
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice.
Abadir PM; Carey RM; Siragy HM
Hypertension; 2003 Oct; 42(4):600-4. PubMed ID: 12953015
[TBL] [Abstract][Full Text] [Related]
5. Myocardial bradykinin following acute angiotensin-converting enzyme inhibition, AT1 receptor blockade, or combined inhibition in congestive heart failure.
Multani MM; Krombach RS; Goldberg AT; King MK; Hendrick JW; Sample JA; Baicu SC; Joffs C; deGasparo M; Spinale FG
J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):369-76. PubMed ID: 11907639
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II type 2 receptor expression after vascular injury: differing effects of angiotensin-converting enzyme inhibition and angiotensin receptor blockade.
Barker TA; Massett MP; Korshunov VA; Mohan AM; Kennedy AJ; Berk BC
Hypertension; 2006 Nov; 48(5):942-9. PubMed ID: 16982965
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats.
Siragy HM; de Gasparo M; Carey RM
Hypertension; 2000 May; 35(5):1074-7. PubMed ID: 10818067
[TBL] [Abstract][Full Text] [Related]
8. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model.
Siragy HM; Carey RM
Hypertension; 1999 May; 33(5):1237-42. PubMed ID: 10334818
[TBL] [Abstract][Full Text] [Related]
9. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Jorde UP; Ennezat PV; Lisker J; Suryadevara V; Infeld J; Cukon S; Hammer A; Sonnenblick EH; Le Jemtel TH
Circulation; 2000 Feb; 101(8):844-6. PubMed ID: 10694521
[TBL] [Abstract][Full Text] [Related]
10. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes.
Spinale FG; Mukherjee R; Iannini JP; Whitebread S; Hebbar L; Clair MJ; Melton DM; Cox MH; Thomas PB; de Gasparo M
Circulation; 1997 Oct; 96(7):2397-406. PubMed ID: 9337216
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
[TBL] [Abstract][Full Text] [Related]
12. Role of kinins and angiotensin II in the vasodilating action of angiotensin converting enzyme inhibition in rat renal vessels.
Endlich K; Steinhausen M
J Hypertens; 1997 Jun; 15(6):633-41. PubMed ID: 9218183
[TBL] [Abstract][Full Text] [Related]
13. Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet.
Lassila M; Finckenberg P; Pere AK; Krogerus L; Ahonen J; Vapaatalo H; Nurminen ML
Br J Pharmacol; 2000 Jul; 130(6):1339-47. PubMed ID: 10903974
[TBL] [Abstract][Full Text] [Related]
14. Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins.
Komers R; Cooper ME
Am J Physiol; 1995 Apr; 268(4 Pt 2):F588-94. PubMed ID: 7733315
[TBL] [Abstract][Full Text] [Related]
15. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
Koid SS; Ziogas J; Campbell DJ
Hypertension; 2014 Apr; 63(4):768-73. PubMed ID: 24420538
[TBL] [Abstract][Full Text] [Related]
16. Renin-angiotensin system modulates renal bradykinin production.
Siragy HM; Jaffa AA; Margolius HS; Carey RM
Am J Physiol; 1996 Oct; 271(4 Pt 2):R1090-5. PubMed ID: 8898005
[TBL] [Abstract][Full Text] [Related]
17. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3', 5'-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats.
Siragy HM; Carey RM
J Clin Invest; 1996 Apr; 97(8):1978-82. PubMed ID: 8621783
[TBL] [Abstract][Full Text] [Related]
18. Regulation of renal 12(S)-hydroxyeicosatetraenoic acid in diabetes by angiotensin AT1 and AT2 receptors.
Abdel-Rahman EM; Abadir PM; Siragy HM
Am J Physiol Regul Integr Comp Physiol; 2008 Nov; 295(5):R1473-8. PubMed ID: 18799632
[TBL] [Abstract][Full Text] [Related]
19. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
Pfeffer MA
Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats.
Webb RL; Navarrete AE; Davis S; de Gasparo M
J Hypertens; 1998 Jun; 16(6):843-52. PubMed ID: 9663925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
